



January 11, 2007

Dear Comnetix Shareholder:

As you know, L-1 Identity Solutions, Inc. (NYSE: ID) has offered to purchase all of the outstanding shares of Comnetix Inc. at a price of US \$1.05 per share in cash. This represents an increase from our original offer of US \$0.82 per share. Our increased offer gives you a premium of more than 150 percent when compared to the price of Comnetix's shares (Cdn\$0.50) before our agreement with Comnetix was first announced in November 2006.

You are probably aware that on December 21, 2006, BIO-key International Inc., an Over-the-Counter (OTC) traded company based in New Jersey, announced its intention to make a share-for-share tender offer for all of the common shares of Comnetix. To date, no actual offer from BIO-key has been made.

For your information and benefit, we have outlined below a number of important observations and perceived risks respecting the purported BIO-key offer and we urge you to consider these issues carefully when considering any purported proposal from BIO-key.

I. L-1 Believes That Our All-Cash Offer is Substantially Superior to Any Share-For-Share Consideration That BIO-Key Would Purport to Offer as Described in its Announcement.

- The revised L-1 offer has been unanimously approved by the Comnetix Board of Directors. The Board has determined that the revised arrangement is fair to, and in the best interests of, Comnetix, its shareholders and warrant holders. The Board of Directors of Comnetix unanimously recommends that Comnetix shareholders and warrant holders vote FOR the special resolution approving the arrangement, as revised.
- The revised L-1 offer is an all-cash transaction that delivers immediate return on investment to Comnetix shareholders, as opposed to a stock-based transaction that carries significant liquidity, market and value risk.

II. BIO-key has No Apparent Track Record of Delivering Shareholder Value.

According to its most recent publicly-available financial statements and filings for the 9-month period ended September 30, 2006:

- BIO-key has continued to sustain losses and had an operating loss of US \$4 million on revenue of US \$11.1 million.
- BIO-key has long-term debt and other obligations of US \$12.6 million and has announced that it will arrange for additional financing for working capital.
- BIO-key has negative cash flow of approximately US \$500,000 per month.
- BIO-key has a working capital deficit, with current liabilities of US \$13.0 million compared to current assets of US \$6.7 million.



- BIO-key has negative stockholders' equity, with assets of US \$22.3 million compared to total liabilities, including redeemable preferred stock, of US \$24.9 million.
- BIO-key's auditors issued a "going concern opinion" regarding the ability of the Company to continue its operations. The March 2006 auditors' report prepared by BIO-key's Certified Public Accountants, raises

"substantial doubt about the Company's ability to continue as a going concern"

- BIO-key has restated its audited financial statements for the years 2003, 2004 and 2005 and its unaudited financial statements for quarters within those years as well as the quarter ended March 31, 2006. BIO-key has reported multiple material weaknesses in its internal controls over financial reporting since 2004 and such material weakness continue to be unremediated.
- BIO-key seems to have a poor reporting record and history of late filings with the U.S. Securities and Exchange Commission (SEC). On at least five occasions (12/31/04, 6/30/05, 9/30/05, 3/31/06 and 6/30/06), BIO-key filings with the SEC were late.

III. BIO-key Stock is a Weak Performer in the Financial Markets.

- BIO-key shares are currently trading near their 52-week low, reflecting the low enthusiasm for the Company's performance and outlook. The chart below highlights the stock's downward trend in 2006.



- BIO-key's average daily trading volume for the past three months is approximately 124,000 shares. This low trading volume will most likely restrict Comnetix shareholders' liquidity with BIO-key stock and may prevent you from realizing the full value of the consideration received. Said another way, with that trading volume, the 65 million shares that BIO-key will need to issue to Comnetix shareholders (see below) represent more than 524 trading days.



- Over the last two years, there has been a precipitous drop in the shares, from a high of US \$1.50 per share to a low of US \$0.30.
- Remember that the L-1 offer is all cash. Under the BIO-key offer, you would receive shares of BIO-key and no cash. You would become a shareholder of BIO-key, a U.S.-based company that currently trades on the OTC Bulletin Board.

IV. The BIO-key Investment Will Be Dilutive, Making Your Shares Worth Less.

BIO-key has failed to provide any specifics on the exchange ratio relative to its offer; therefore, the number of actual shares that each Comnetix shareholder would receive is unknown. However, based on BIO-key financial statements and public statements about its intended tender offer to Comnetix shareholders, BIO-key would need to issue approximately 65 million additional shares (beyond the 90 million of outstanding shares, options, warrants and convertible securities) in order to complete its acquisition of all of Comnetix's outstanding shares. This means that BIO-key would have approximately 155 million shares outstanding on a fully-diluted basis, after taking into account the exercise of BIO-key's currently outstanding options, warrants and other convertible securities. This does not reflect the impact of anti-dilution rights that certain Bio-key shareholders may already have.

V. The BIO-key Offer May Involve Timing Risks Associated with the Registration of BIO-key Securities.

L-1 assumes that in order for BIO-key shareholders to receive shares of BIO-key stock that are registered and freely transferable, such shares will need to be registered on a registration statement that must be reviewed and declared effective by the SEC prior to the issuance of the shares. Given BIO-key's history of apparent internal controls issues, including without limitation, late filings with the SEC on 12/31/04, 6/30/05, 9/30/05, 3/31/06 and 6/30/06, and the restatements of BIO-key's audited financial statements for 2003, 2004 and 2005, and the unaudited financial statements for quarters within those years and the quarter ended March 31, 2006, there can be no assurance that the SEC will complete its review in a timely manner or that it will ultimately declare a BIO-key registration statement effective on a timely basis.

VI. Additional Considerations.

- The dissident circular filed by Northern Financial Corporation represents that prior to the announcement of Comnetix's agreement with L-1, BIO-key and Comnetix held discussions about an all-share offer from BIO-key at a price of US \$1.29 per share. Northern Financial Corporation's dissident Financial Circular further claims that Comnetix "abruptly terminated negotiations with BIO-key and surprisingly opted" for L-1's offer. Comnetix has publicly stated that no such offer was made by BIO-key. For all the reasons described in this letter, L-1 believes that, should any such purported offer be made, it would be grossly inferior to the L-1 all-cash offer.



- Both transactions are taxable; however, there is an important distinction. The L-1 offer provides you with immediate liquidity of cash to pay any taxes on the transaction; the liquidity of any consideration received in the form of BIO-key stock is suspect for the many reasons described above.
- Northern Financial Corporation has a conflict of interest that will cost you money. Specifically, the Northern Financial dissident proxy circular states that if the BIO-key offer is completed, Northern Financial Corporation will arrange for financing of US \$5 million through its subsidiary, Northern Securities Inc., a broker and investment dealer. We assume that Northern Securities Inc. will require an as yet undisclosed fee or commission to be paid by BIO-key.
- Northern Financial does not guarantee any appreciation in value to take place as a result of the exchange of your ComnetiX shares for BIO-key shares. Furthermore, in its dissident proxy circular, Northern Financial states that any “significant appreciation” in the value of the combined BIO-key and ComnetiX that may occur will be between 12-18 months out.

ComnetiX is soliciting your proxy and vote and we urge you to carefully read the ComnetiX management information circular dated December 18, 2006, as amended on January 10, 2007, for further information.

Sincerely,

A handwritten signature in black ink, appearing to read 'R. LaPenta', with a long horizontal flourish extending to the right.

Robert V. LaPenta
Chairman of the Board, President & Chief Executive Officer
L-1 Identity Solutions, Inc.